Morgan Stanley Reiterates Overweight on St. Jude Medical

Morgan Stanley maintains St. Jude Medical

at Overweight after inconclusive data from the Durata case. Morgan Stanley remarks, “Several unanswered questions surround the Durata case report today. The center and explanting physician need to be determined and the lead must be adjudicated. Before that, any determination is premature, in our view. Recall that several prior MAUDE reports of Durata externalized conductors driven by inside-out insulation breach were later determined to be erroneous. Fortunately, this process begins with physician identification and could occur in a matter of days.” STJ closed at $36.24 on Tuesday.